Table I.
Baseline characteristics of atopic and nonatopic children with a wheezing episode and children without a wheezing episode during the study period
| Atopic wheezers∗ (n = 25) | Nonatopic wheezers∗ (n = 18) | Children with no episode† (n = 46) | |
|---|---|---|---|
| Age (y) | 5 ± 0.5 | 5 ± 0.6 | 4.5 ± 0.3 |
| Male sex, no. | 14 (56%) | 9 (50%) | 20 (44%) |
| Height (m) | 1.11 ± 0.07 | 1.15 ± 0.05 | 1.07 ± 0.05 |
| Atopic | 25 | 0 | 21 (46%) |
| Baseline Feno (ppb) | 10 (7-11) | 8.5 (6-10) | 9.1 (7-10) |
| Baseline FEV0.5 (L) | 0.97 (0.9-1.07) | 1 (0.92-1.07) | 0.94 (0.747-1.139) |
| Baseline FVC (L) | 1.274 ± 0.266 | 1.336 ± 0.191 | 1.141 ± 0.17 |
| Baseline PEF (L/min) | 158.1 (136.8-198.6) | 157.8 (153-177) | 151.4 (140-178.7) |
| Previously treated with bronchodilators alone‡ | 18 (72%) | 14 (77.8%) | 32 (69.6%) |
Values are presented as means ± SDs or medians (IQRs) unless otherwise reported
FVC, Forced vital capacity.
∗
Baseline values obtained 8 weeks before the recorded wheezing episode.
†
Baseline values obtained at recruitment and atopic status at the age of 6 years.
‡
The rest of the children had been treated before enrollment with inhaled corticosteroids, montelukast, or both.